Capricor Therapeutics, Inc.
CAPR$3.80
$-2.77 (-42.16%)
OpenNegative FDA briefing docs for July 29 AdCom trigger CAPR's 62% premarket plunge
Loading chart...
IndexN/A
Market Cap0.22B
Enterprise Value1.07B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-1.64
P/SN/A
P/B4.39
P/C-18.45
EV/EBITDA-10.70
EV/SalesN/A
EPS (ttm)-2.32
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume22.80M
Shs Outstand0.06B
Change-42.16%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Today01:52PMCAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC(globenewswire.com)01:24PMCAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash(prnewswire.com)01:00PMCAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law(gurufocus.com)12:38PMLowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws(globenewswire.com)12:09PMCAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law(businesswire.com)10:24AMCAPR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Capricor(prnewswire.com)09:30AMCapricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel(globenewswire.com)08:53AMCAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation(globenewswire.com)08:06AMCapricor plummets after FDA panel votes against Duchenne heart disease therapy(reuters.com)04:00AMRosen Law Firm Encourages Capricor Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - CAPR(gurufocus.com)03:58AMRosen Law Firm Encourages Capricor Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - CAPR(prnewswire.com)
Yesterday10:51PMCAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash(globenewswire.com)10:51PMCAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash(globenewswire.com)07:29PMSecurities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm(prnewswire.com)06:45PMCapricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)(prnewswire.com)06:08PMCAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm(globenewswire.com)05:13PMFDA panel votes against Capricor's Duchenne heart disease therapy(reuters.com)10:05AMThe Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy(globenewswire.com)07:45AMCAPR INVESTIGATION: Capricor Therapeutics Investors Should Contact Block & Leviton About Recovering Their Losses(newsfilecorp.com)04:48AMAlly Bridge Group NY LLC Takes $3.46 Million Position in Capricor Therapeutics, Inc. $CAPR(defenseworld.net)04:09AMADAR1 Capital Management LLC Buys Shares of 90,593 Capricor Therapeutics, Inc. $CAPR(defenseworld.net)
Jul 2808:00PMCAPR INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud(globenewswire.com)12:00PMSecurities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP(businesswire.com)10:00AMCapricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation(gurufocus.com)09:00AMCapricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation(businesswire.com)
Jul 2709:00PMRosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation -- CAPR(gurufocus.com)08:36PMRosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR(businesswire.com)06:34PMSecurities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz(businesswire.com)01:58PMCapricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel(globenewswire.com)01:53PMCAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC(globenewswire.com)
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.27M | $25.18M | $2.55M | $244.90K | $310.25K | $1.01M | $1.67M | $2.67M |
| Cost of Revenue | $49.97M | $36.45M | $21.82M | N/A | N/A | $5.14M | N/A | N/A |
| Gross Profit | $-27.70M | $-11.27M | $-19.27M | $244.90K | $310.25K | $-4.14M | $1.67M | $2.67M |
| Gross Margin | -124.37% | -44.76% | -755.07% | 100.00% | 100.00% | -411.61% | 100.00% | 100.00% |
| Operating Expenses | $14.87M | $12.81M | $10.43M | $21.18M | $14.00M | $3.60M | $17.00M | $15.53M |
| Operating Income | $-42.56M | $-24.08M | $-29.70M | $-20.94M | $-13.69M | $-7.73M | $-15.33M | $-12.86M |
| Operating Margin | -191.13% | -95.63% | -1163.93% | -8549.86% | -4412.56% | -769.52% | -917.24% | -482.45% |
| Net Income | $-40.47M | $-22.29M | $-29.02M | $-20.02M | $-13.66M | $-7.64M | $-15.19M | $2.43M |
| Net Margin | -181.71% | -88.52% | -1137.37% | -8175.86% | -4401.94% | -760.36% | -909.10% | 91.19% |
| EPS (Basic) | $-1.15 | $-0.83 | $-1.18 | $-0.87 | $-0.88 | $-2.06 | $-5.17 | $1.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Discover more
You may be interested in